Lajos Pusztai, MD
Enriched profileProfessor of Medicine (Medical Oncology); Chief, Breast Medical Oncology Section, Yale Cancer Center · Yale University
Lajos Pusztai is Professor of Medicine (Medical Oncology); Chief, Breast Medical Oncology Section, Yale Cancer Center at Yale University. OpenAlex indexes 1,394 publications with 69,704 citations (h-index 114); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Lajos Pusztai as a Highly Cited Researcher (Clinical Medicine, 2014-2016; Cross-Field, 2019).
Data verified 21 Sept 2026
Overview
Updated 14 Oct 2026
Lajos Pusztai, M.D., D.Phil, is Professor of Medicine (Medical Oncology) at Yale University / Yale School of Medicine / Yale Cancer Center, New Haven, CT. The public record shows 1,394 publications with 69,704 citations (h-index 114), centered on Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer Genomics and Diagnostics. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 16 companies, 2 NIH-funded awards (2017–2026).
- Most recent indexed publication: 2026 · bioRxiv
- Top research focus: Breast Cancer Treatment Studies
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 78 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 450.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Sponsor: Natera, Inc.
Industry payments
Updated 14 Oct 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20253 payments$17,070openpaymentsdata.cms.gov ↗
- AstraZeneca UK LimitedProgram year20255 payments$12,569openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year20257 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor91.2%Anastrozole100%Part D≥45 patientsKinase inhibitor8.8%Verzenio100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
2 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:
- Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer
Arizona State University-Tempe Campus
FY2026$632,461R01CA286128 - Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer
Arizona State University-Tempe Campus
FY2025$643,798R01CA286128
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets.
Clinical cancer research
Article2026 - Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer.
JNCI cancer spectrum
Clinical Trial2026 - Current Management Practices of De Novo Oligometastatic Breast Cancer: Real-World Data From a Physician Survey.
JCO oncology practice
Article2026
Most-cited works
by citation count (OpenAlex)- 01Pembrolizumab for Early Triple-Negative Breast Cancer3,125 citations2020
- 02
- 03
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/lajos-pusztai-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Lajos-Pusztai
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
medicine.yale.edu/media-player/meet-dr-lajos-pusztai
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Other
oncodaily.com/opinion/lajos-pusztai-499158
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - Spotify
open.spotify.com/episode/71bynnsi2wxyJg5MCQnz4h
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Editorial & leadership roles
journal and society appointments- Chief
Breast Medical Oncology Section, Yale Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →yalecancercenter.org ↗ - Co-Leader
Genetics, Genomics and Epigenetics Program, Yale Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Scientific Co-Director
Center for Breast Cancer, Yale Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Chair
Breast Cancer Research Committee, Southwest Oncology Group (SWOG)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →swog.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine201420152016verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
- Cross-Field2019verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- Fellow of the American Society of Clinical Oncology (FASCO)
credential confirmed, but exact election year uncertain; a primary Yale School of Medicine source ("Dr …
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.yale.edu ↗
Secondary affiliations
appointments beyond the home institution- Member
Scientific Advisory Board, Breast Cancer Research Foundation (BCRF); BCRF Investigator since 2002
2002provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcrf.org ↗ - Internal Medicine
Yale School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Computational Biology and Biomedical Informatics
Yale School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →yalemedicine.org ↗
- Yale New Haven Hospital
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ynhh.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ventures.yale.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- Podcast guest
"Oncology Today with Dr Neil Love" - 5-Minute Journal Club Issue 2: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com ↗ - Featured video profile
"Meet Dr. Lajos Pusztai", Yale Cancer Center media player
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Author/contributor
CancerNetwork
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
John Krystal, MD
Yale University
Lee Schwamm, MD
Yale University
Naftali Kaminski, MD
Yale University
Eric Velazquez, MD
Yale University
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles